Newsbenzinga
FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio
· Published
Article summary
Merck's Lipfendra wins FDA approval as the first oral PCSK9 inhibitor for adults with high LDL cholesterol after positive Phase 3 results.
An excerpt from the original article.
Comments —
Loading comments…